Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo
Journal of Korean Medical Science
;
: 1385-1395, 2017.
Artículo
en Inglés
| WPRIM
| ID: wpr-200245
ABSTRACT
We estimated the effect of various immunosuppressants (ISs) and metformin (M) to provide theoretical background of optimal therapeutic strategy for de novo colon cancer after liver transplantation (LT). Three colon cancer cell lines (HT29, SW620, and HCT116) were used in in vitro studies. HT29 was also used in BALB/c-nude mice animal models. Following groups were used in both in vitro and in vivo studies sirolimus (S), tacrolimus (T), cyclosporin A (CsA), M, metformin/sirolimus (Met/S), metformin/tacrolimus (Met/T), and metformin/cyclosporin A (Met/CsA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed and western blot analyses were performed for mTOR pathway proteins, apoptosis proteins, and epithelial-mesenchymal-transition (EMT) proteins. Tumor volume was measured for 4 weeks after inoculation. MTT-assay revealed significant cell viability inhibition in all 3 colon cancer cell lines in groups of S, M, and Met/S. Of note, group Met/S showed synergistic effect compare to M or S group. Western blot analysis showed significant low levels of all investigated proteins in groups of S and Met/S in both in vitro and in vivo experiment. Tumor growth was significantly inhibited only in the Met/S group. Combination of Met and S showed the most potent inhibition in all colon cancer cell lines. This finding might have application for de novo colon cancer.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Técnicas In Vitro
/
Línea Celular
/
Supervivencia Celular
/
Western Blotting
/
Terapia de Inmunosupresión
/
Trasplante de Hígado
/
Tacrolimus
/
Ciclosporina
/
Apoptosis
/
Colon
Límite:
Animales
Idioma:
Inglés
Revista:
Journal of Korean Medical Science
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS